Equities

Shanghai Henlius Biotech Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Shanghai Henlius Biotech Inc

Actions
  • Price (HKD)64.00
  • Today's Change-1.55 / -2.36%
  • Shares traded805.50k
  • 1 Year change+131.88%
  • Beta0.9149
Data delayed at least 15 minutes, as of Mar 03 2026 08:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2024202420232022
ASSETS
Cash And Short Term Investments773988841
Total Receivables, Net925865508
Total Inventory728757757
Prepaid expenses444455
Other current assets, total412231
Total current assets2,5122,6762,192
Property, plant & equipment, net2,7002,6532,230
Goodwill, net------
Intangibles, net5,3554,5114,332
Long term investments------
Note receivable - long term------
Other long term assets1616--
Total assets10,5989,9048,924
LIABILITIES
Accounts payable729545714
Accrued expenses1,0371,059854
Notes payable/short-term debt000
Current portion long-term debt/capital leases2,5602,8002,522
Other current liabilities, total706663912
Total current liabilities5,0325,0675,002
Total long term debt1,0891,2931,155
Total debt3,6484,0933,677
Deferred income tax------
Minority interest------
Other liabilities, total1,4631,3511,131
Total liabilities7,5847,7117,288
SHAREHOLDERS EQUITY
Common stock543543543
Additional paid-in capital6,0696,0696,052
Retained earnings (accumulated deficit)(3593)(4414)(4952)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(6.15)(7)(7.02)
Total equity3,0142,1921,636
Total liabilities & shareholders' equity10,5989,9048,924
Total common shares outstanding543543543
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.